Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Ampligen Launch For Chronic Fatigue Syndrome Could Come In Late 2007

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

NDA is on track for filing by year-end, with Hemispherx planning to seek a priority review, CEO tells “The Pink Sheet” DAILY.

You may also be interested in...



Hemispherx Submits NDA For First-Ever Chronic Fatigue Syndrome Therapy

Complete Ampligen NDA was submitted to FDA Oct. 10, CEO Carter tells “The Pink Sheet” DAILY.

Hemispherx Submits NDA For First-Ever Chronic Fatigue Syndrome Therapy

Complete Ampligen NDA was submitted to FDA Oct. 10, CEO Carter tells “The Pink Sheet” DAILY.

Ampligen NDA Could Benefit From Increased CDC Attention To Fatigue

CDC research could highlight the need for approval of Hemispherx’ chronic fatigue therapy, the company says.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Global Pharma Guidance Tracker – March 2024

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

See All
UsernamePublicRestriction

Register

PS063521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By